Form 4: Supernus Pharmaceuticals Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Padmanabh P. Bhatt, a Supernus Pharmaceuticals executive, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On March 12, 2024, Padmanabh P. Bhatt, Sr. VP of IP, CSO at Supernus Pharmaceuticals, exercised employee stock options to acquire 3,884 shares of common stock at a price of $12.98 per share.
• Simultaneously, Bhatt sold 3,884 shares of common stock at a weighted average price of $32.99, with individual sales ranging from $32.98 to $33.00.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on September 7, 2023.
• Following these transactions, Bhatt directly owns 8,570 shares of Supernus Pharmaceuticals common stock and 36,116 employee stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity under a pre-existing plan.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives and their potential alignment with shareholder interests. The use of a 10b5-1 trading plan suggests a pre-planned and compliant approach to managing personal investments.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an executive, but the existence of a 10b5-1 plan mitigates concerns about opportunistic trading.

Key Dates